| Bio Roundup: Agile Approval, Coronavirus Collabs, Spruce’s $88M & More | Sarah de Crescenzo | 02/21/20 | National |
| SeaGen Adds Five Prime Therapeutics Antibodies in Licensing Deal | Sarah de Crescenzo | 02/20/20 | Seattle |
| Spruce Bio Raises $88M for Clinical Tests of Rare Endocrine Disease Drug | Frank Vinluan | 02/20/20 | San Francisco |
| EnClear Therapies Nets $10M to Test Neuro Disease ‘Dialysis’ Device | Sarah de Crescenzo | 02/19/20 | Boston |
| Teva Drug Fails to Beat Placebo in Pediatric Tourette Patient Trials | Sarah de Crescenzo | 02/19/20 | National |
| Xcelerating Life Sciences Boston Will Explore Biopharma’s Future in Digital Health | Editors | 02/19/20 | Boston |
| ResTORbio Pins “Strategic Alternatives” Pitch to Parkinson’s Promise | Frank Vinluan | 02/19/20 | Boston |
| Five Prime, Bristol Pancreatic Cancer Drug Combo Fails Phase 2 Test | Sarah de Crescenzo | 02/18/20 | San Francisco |
| Imara Reveals IPO Plan as Sickle Cell Drug Advances in the Clinic | Frank Vinluan | 02/18/20 | Boston |
| New Meds Set to Reshape US CNS and Oncology Markets | Gareth Macdonald | 02/18/20 | National |
| Agile Therapeutics Wins FDA Nod for Twirla Contraceptive Patch | Frank Vinluan | 02/14/20 | New York |
| Bio Roundup: Goodbye Belviq, LogicBio on Hold, Revolution’s IPO & More | Frank Vinluan | 02/14/20 | National |
| Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks | Frank Vinluan | 02/13/20 | National |
| Revolution Medicines IPO Reels In $238M to Take On RAS in Cancer | Frank Vinluan | 02/12/20 | San Francisco |
| Ligand’s Icagen Deal Brings Neuro, CF Assets Plus Partnering Potential | Frank Vinluan | 02/12/20 | San Diego |
| CRISPR, CAR-T, Consolidation: Top Advanced Therapy Milestones of 2019 | Dan Stanton | 02/12/20 | National |
| Two Big Pharma Alliances End in Nixed Deals. Here’s What Happened. | Frank Vinluan | 02/11/20 | National |
| FDA Clinical Hold Stops LogicBio’s Gene Editing Study Before It Starts | Frank Vinluan | 02/10/20 | Boston |
| Wave Life Sciences’ Stumble in Duchenne Leads to 22% Staff Layoff | Frank Vinluan | 02/10/20 | Boston |
| Biohaven Drug Fails Anxiety Study, Data in OCD and More Still to Come | Frank Vinluan | 02/10/20 | New York |
| Eli Lilly, Roche Drugs Fail to Move Needle in Genetically Driven Alzheimer’s | Frank Vinluan | 02/10/20 | National |
| Bio Roundup: POTUS on Prices, a16z’s Fund, Aimmune’s Approval & More | Sarah de Crescenzo | 02/07/20 | National |
| Sonoma Bio Launches With $40M to Take Cell Therapy Beyond Cancer | Frank Vinluan | 02/06/20 | San Francisco |
| Scripps Research’s Calibr to Test “Switchable” CAR-T in Clinical Trial | Sarah de Crescenzo | 02/06/20 | San Diego |
| Early Bird Sale Ending for San Diego’s Xcelerating Life Sciences Conference | Editors | 02/06/20 | National |
| Beam Therapeutics IPO Raises $180M After Nearly Doubling Shares Offered | Sarah de Crescenzo | 02/06/20 | Boston |
| Coda Bio Acquires Drug Candidates to Pair With Engineered Receptors | Sarah de Crescenzo | 02/06/20 | San Francisco |
| Aimmune Gets $200M From Nestlé; Licenses Food Allergy Drug Candidate | Sarah de Crescenzo | 02/05/20 | San Francisco |
| Merck Charts an R&D-Focused Course Starting With a $6.5B Spinoff | Frank Vinluan | 02/05/20 | New York |
| Titan Medical’s Cash Crunch Stalls Plans to Get Surgical Robot to FDA | Frank Vinluan | 02/04/20 | National |
